Charles Cerveny resumes & CV records
Resumes
Scientist In Biology At Phaserx Pharmaceuticals, Inc
Location:
Greater Seattle Area
Industry:
Biotechnology
Charles G Cerveny, Age 56339 NE 91St St, Seattle, WA 98115
Charles Cerveny Phones & Addresses
339 91St St, Seattle, WA 98115
215 Main St, Pullman, WA 99163
Fort Collins, CO
Evanston, IL
Boulder, CO
Social networks
Charles G Cerveny
Linkedin
Industries
Biotechnology
Mentions for Charles G Cerveny
Publications & IP owners
Us Patents
Cd19 Binding Agents And Uses Thereof
US Patent:
8242252, Aug 14, 2012
Filed:
May 17, 2011
Appl. No.:
13/109957
Inventors:
Charlotte McDonagh - Waltham MA, US
Charles G. Cerveny - Seattle WA, US
Dennis Benjamin - Redmond WA, US
Paul Carter - Mercer Island WA, US
Hans Peter Gerber - Bellevue WA, US
Leigh Francisco - Woodway WA, US
Charles G. Cerveny - Seattle WA, US
Dennis Benjamin - Redmond WA, US
Paul Carter - Mercer Island WA, US
Hans Peter Gerber - Bellevue WA, US
Leigh Francisco - Woodway WA, US
Assignee:
Seattle Genetics, Inc. - Bothell WA
International Classification:
C07H 21/04
US Classification:
536 2353
Abstract:
This invention relates to CD 19 binding agents and methods of using such CD 19 binding agents for treating disease.
Methods Of Treating Drug-Resistant Cancers
US Patent:
8512707, Aug 20, 2013
Filed:
Apr 19, 2010
Appl. No.:
12/762843
Inventors:
Svetlana O. Doronina - Snohomish WA, US
Charles G. Cerveny - Seattle WA, US
Alan F. Wahl - Mercer Island WA, US
Charles G. Cerveny - Seattle WA, US
Alan F. Wahl - Mercer Island WA, US
Assignee:
Seattle Genetics, Inc. - Bothell WA
International Classification:
A61K 39/395
US Classification:
4241811, 4241781
Abstract:
Methods of treating a refractory or drug resistant cancer, cell proliferative disorder and tumor cells are provided.
Anti-Cd20 Antibody-Drug Conjugates For The Treatment Of Cancer And Immune Disorders
US Patent:
2005018, Aug 18, 2005
Filed:
Jul 30, 2003
Appl. No.:
10/632151
Inventors:
Alan Wahl - Mercer Island WA, US
Peter Senter - Seattle WA, US
Charles Cerveny - Seattle WA, US
Peter Senter - Seattle WA, US
Charles Cerveny - Seattle WA, US
International Classification:
A61K039/395
C07K016/46
C07K016/46
US Classification:
424144100, 424178100, 530391100
Abstract:
The present invention relates to methods and compositions for the treatment of CD20-expressing cancers and immune disorders involving CD20-expressing cells. The present methods comprise administering to a subject an anti CD20 antibody-drug conjugate that has a high potency and/or is capable of internalizing into CD20-expressing cells. The present invention further provides pharmaceutical compositions and kits comprising such conjugates. The present invention yet further provides methods of and compositions relating to combination therapy of cancer and immune disorders involving CD20-expressing cells using the anti-CD20 antibody-drug conjugates of the invention.
Cd19 Binding Agents And Uses Thereof
US Patent:
2009013, May 28, 2009
Filed:
Oct 17, 2008
Appl. No.:
12/253895
Inventors:
Charlotte McDonagh - Waltham MA, US
Charles G. Cerveny - Seattle WA, US
Dennis Benjamin - Redmond WA, US
Paul Carter - Mercer Island WA, US
Hans-Peter Gerber - Bellevue WA, US
Leigh Francisco - Woodway WA, US
Charles G. Cerveny - Seattle WA, US
Dennis Benjamin - Redmond WA, US
Paul Carter - Mercer Island WA, US
Hans-Peter Gerber - Bellevue WA, US
Leigh Francisco - Woodway WA, US
Assignee:
Seattle Genetics, Inc. - Bothell WA
International Classification:
A61K 39/395
C07K 16/18
C12N 15/11
C07K 16/18
C12N 15/11
US Classification:
4241791, 5303873, 5303917, 536 2353
Abstract:
This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.
Cd37 Immunotherapeutic And Combination With Bifunctional Chemotherapeutic Thereof
US Patent:
2009027, Nov 5, 2009
Filed:
Apr 13, 2009
Appl. No.:
12/422780
Inventors:
Phillip Tan - Lynnwood WA, US
Sandy A. Simon - Seattle WA, US
Charles G. Cerveny - Seattle WA, US
Christy Anne Nilsson - Sammamish WA, US
William Brady - Bothell WA, US
Jeffrey A. Ledbetter - Shoreline WA, US
Peter A. Thompson - Bellevue WA, US
Cecile Morales - Seattle WA, US
Sandy A. Simon - Seattle WA, US
Charles G. Cerveny - Seattle WA, US
Christy Anne Nilsson - Sammamish WA, US
William Brady - Bothell WA, US
Jeffrey A. Ledbetter - Shoreline WA, US
Peter A. Thompson - Bellevue WA, US
Cecile Morales - Seattle WA, US
Assignee:
Trubion Pharmaceuticals, Inc. - Seattle WA
International Classification:
A61K 39/395
C07K 16/18
C07H 21/04
C12N 15/74
C12N 1/00
A61P 35/00
C07K 16/18
C07H 21/04
C12N 15/74
C12N 1/00
A61P 35/00
US Classification:
4241331, 5303873, 536 2353, 4353201, 435243
Abstract:
The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
Cd37 Immunotherapeutic Combination Therapies And Uses Thereof
US Patent:
2010013, Jun 3, 2010
Filed:
Nov 13, 2009
Appl. No.:
12/618509
Inventors:
CHARLES G. CERVENY - SEATTLE WA, US
PETER A. THOMPSON - BELLEVUE WA, US
PETER A. THOMPSON - BELLEVUE WA, US
Assignee:
TRUBION PHARMACEUTICALS, INC. - SEATTLE WA
International Classification:
A61K 51/00
A61K 31/436
A61K 31/12
A61K 31/60
A61K 39/395
A61K 38/00
A61K 31/415
A61K 31/436
A61K 31/12
A61K 31/60
A61K 39/395
A61K 38/00
A61K 31/415
US Classification:
424 111, 514291, 514685, 514159, 4241301, 4241331, 514 12, 514394
Abstract:
The present disclosure provides methods for using CD37-specific binding molecules (such as a CD37-specific SMIP or antibody) in combination with mTOR inhibitors (such as rapamycin and derivatives or analogues thereof) or phosphatidylinositol 3-kinase (PI3K) inhibitors (such as p110δ-specific inhibitors or the like), which can be done concurrently or sequentially, to treat or prevent a B-cell related hyperproliferative disease, such as a lymphoma, carcinoma, myeloma, or the like.
Cd37 Immunotherapeutic And Combination With Bifunctional Chemotherapeutic Thereof
US Patent:
2011017, Jul 14, 2011
Filed:
Apr 11, 2009
Appl. No.:
12/678857
Inventors:
Philip Tan - Edmonds WA, US
Sandy Alexander Simon - Seattle WA, US
Charles G. Cerveny - Seattle WA, US
Christy Anne Nilsson - Sammamish WA, US
William Brady - Bothell WA, US
Jeffrey A. Ledbetter - Shoreline WA, US
Peter Armstrong Thompson - Bellevue WA, US
Cecile Morales - Seattle WA, US
Sandy Alexander Simon - Seattle WA, US
Charles G. Cerveny - Seattle WA, US
Christy Anne Nilsson - Sammamish WA, US
William Brady - Bothell WA, US
Jeffrey A. Ledbetter - Shoreline WA, US
Peter Armstrong Thompson - Bellevue WA, US
Cecile Morales - Seattle WA, US
Assignee:
TRUBION PHARMACEUTICALS, INC. - Seattle WA
International Classification:
A61K 39/395
C07K 16/00
A61P 35/00
C07K 16/00
A61P 35/00
US Classification:
4241331, 5303871, 4241301
Abstract:
The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.
Cd19 Binding Agents And Uses Thereof
US Patent:
2012029, Nov 22, 2012
Filed:
Jun 21, 2012
Appl. No.:
13/530074
Inventors:
Charlotte McDonagh - Waltham MA, US
Charles G. Cerveny - Seattle WA, US
Dennis Benjamin - Redmond WA, US
Paul Carter - Mercer Island WA, US
Hans Peter Gerber - Bellevue WA, US
Leigh Francisco - Woodway WA, US
Charles G. Cerveny - Seattle WA, US
Dennis Benjamin - Redmond WA, US
Paul Carter - Mercer Island WA, US
Hans Peter Gerber - Bellevue WA, US
Leigh Francisco - Woodway WA, US
Assignee:
Seattle Genetics, Inc. - Bothell WA
International Classification:
A61K 39/395
A61P 35/02
A61P 35/00
A61P 35/02
A61P 35/00
US Classification:
4241331, 4241731, 4241781, 4241811
Abstract:
This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.
NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.